

FACULTY DETAILS

I. **Name:** Mohd Adil Shareef



II. **Designation:** Assistant Professor

III. **Date of Joining:** 24/10/2013

IV. **Date of Birth:** 21/11/1987

V. **Email Id:** adilshareef07@gmail.com

VI. Educational Qualification:

1. **B. Pharm:** Anwar Ul Uloom College Of Pharmacy (JNTUH), 2010

2. **M.Pharm:** Sultan Ul Uloom College Of Pharmacy (JNTUH), 2012

Specialization: Pharmaceutical chemistry

3. **Ph.D.:** Academy of Scientific and industrial research, CSIR-IICT Hyderabad, 2020 (**Ph.D. thesis submitted**)

Title of Ph.D. thesis: “Synthesis and biological studies of imidazo. indolo and indenopyrazole heterocyclics as potential chemotherapeutic agents”

VII. International Publications:

1. New Indolyl-Arylamino propeAnone Conjugates: Synthesis, Cytotoxicity and Apoptotic Inducing Studies. **Mohd Adil Shareef**, T. Ganapathi, I. Khan, S. Rani, A. Rajanna, S. Akbar, C. G. Kumar and B. Nagendra Babu. *ChemistrySelect*, 2020, 5, 2063–2069.
2. Synthesis of new triazole fused imidazo[2,1-*b*]thiazole hybrids with emphasis on *Staphylococcus aureus* virulence factors. **Mohd Adil Shareef**, K. Sirisha, I. Bin Sayeed, I. Khan, T. Ganapathi, S. Akbar, C. G. Kumar, A. Kamal and B. Nagendra Babu. *Bioorg. Med. Chem. Lett*, 2019, 29, 126621–126626.
3. Design, synthesis, and antimicrobial evaluation of 1,4-dihydroindeno[1,2-*c*]pyrazole tethered carbonylhydrazone hybrids: exploring their in silico ADMET, ergosterol inhibition and ROS inducing potential. **Mohd Adil Shareef**, K. Sirisha, I. Khan, I. Bin Sayeed,, S.S. Jhadav, G. Ramu, C. G. Kumar, A. Kamal and B. Nagendra Babu. *Medchemcommun*, 2019, 10, 806–813.

4. Design, Synthesis and Biological Evaluation of Substituted (1-(4-chlorobenzyl)-1*H*-indol-3-yl) 1*H*-(1,2,3-triazol-4-yl) methanones as Antifungal Agents. **Mohd Adil Shareef**, H. Rajpurohit, K. Sirisha, I. Bin Sayeed, I. Khan, M. Kadagathur, T. Ganapathi, C. G. Kumar, A. Kamal and B. Nagendra Babu. *ChemistrySelect*, 2019, 4, 2258–2266.
5. A comprehensive review on the therapeutic versatility of imidazo[2,1-*b*]-thiazoles. **Mohd Adil Shareef**, I. Khan, B. Nagendra Babu and A. Kamal. *Curr. Med. Chem.* 2019, 26, 1–14.
6. Investigation of Podophyllotoxin Esters as Potential Anticancer Agents: Synthesis, Biological Studies and Tubulin Inhibition Properties. **Mohd Adil Shareef**, D. Duscharla, G. Ramasatyaveni, N.R. Dhoke, A. Das, R. Ummanni, A. K. Srivastava. *Eur. J. Med. Chem.* 2015, 89, 128–137.
7. Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-*c*]pyrazole chalcone as EGFR /Akt pathway inhibitors. I. Khan, K.R. Garikapati, A. Setti, A. B. Shaik, V. K. K. Makani, **M. A. Shareef**, H. Rajpurohit, V. Namrathatha, M. Pal-Bhadra, A. Kamal, C. G. Kumar. *Eur. J. Med. Chem.* 2019, 163, 636–648
8. One pot synthesis and biological evaluation of arylpropenone aminochalcone conjugates as potential apoptosis inducers. I. Khan, T. Ganapathi, **M. A. Shareef**, A. B. Shaik, S. Akbar, A. Rajanna, A. Kamal, C.G. Kumar. *ChemistrySelect*, 2019, 4, 4672–4678.
9. Synthesis of new bis-pyrazole linked hydrazides and their *in vitro* evaluation as antimicrobial agent: A mechanistic role in *Candidal* biofilm and ergosterol biosynthesis inhibition. I. Khan, K. Sirisha, **M. A. Shareef**, T. Ganapathi, A. B. Shaik, K. C. Shekar, A. Kamal and C. G. Kumar. *Chem Biol Drug Des.* 2019, 94, 1339–1351.
10. Synthesis and biological evaluation of pyrazole linked benzothiazole- β -naphthol derivatives as topoisomerase I inhibitors with DNA binding ability. B. Nagaraju, J. Kovvuri, C. G. Kumar, S. Rani Routhu, **M. A. Shareef**, S. Alavala, N. Nagesh and A. Kamal. *Bioorg. Med. Chem.*, 27, 2019, 708-720,
11. An overview on the synthetic and medicinal perspectives of indenopyrazoles. I. Khan, **M. A. Shareef** and C. G. Kumar. *Eur. J. Med. Chem.* 2019, 178, 1–12.
12. Design, synthesis and biological evaluation of 1, 4-dihydro indeno[1,2- *c*] pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis. I. Khan, K. R. Garikapati , A. B. Shaik , V. K. K. Makani, A.

- Rahim, **M. A. Shareef**, V. G. Reddy, M. Pal-Bhadra, A. Kamal and C. G. Kumar. *Eur. J. Med. Chem.* 2018, *144*, 104–115.
13. Development of pyrrolo[2,1-c][1,4]benzodiazepine b-glucoside prodrugs for selective therapy of cancer. A.P. Reddy, V. Tekumalla, I. Bin Sayeed , V. L. Nayak, A. Nagarajan, **M. A. Shareef**, B. Nagaraju and A.Kamal, *Bioorg. Chem.* 2018, *76*, 288–293.
 14. Design, synthesis and biological evaluation of imidazopyridinepropenone conjugates as potent tubulin inhibitors. I. Bin Sayeed, V. L. Nayak, **M. A. Shareef**, N. K. Chouhan and A. Kamal. *Med. Chem. Commun*, 2017, *8*, 1000–1006.
 15. Design, Synthesis of Phenstatin/isocombretastatin-Oxindole Conjugates as Antimitotic agents. G. B. Kumar, V. L. Nayak, I. Bin Sayeed· V. S. Reddy, A. B. Shaik, R. Mahesh, M. F. Baig, **M. A. Shareef**, A. Ravikumar and A.Kamal. *Bioorg. Med. Chem*, 2016 , *24*, 1729–1740.
 16. Development and Biological Evaluation of Imidazothiazole propenones as Tubulin Inhibitors that effectively triggered Apoptotic Cell Death in Alveolar Lung Cancer Cell Line. I. Bin Sayeed, K. R.Garikapati, V. K. K. Makani, A. Nagarajan, **M. A. Shareef**, A. Alarifi, M. Pal-Bhadra and A. Kamal. *ChemistrySelect*, 2017, *2*, 6480–6487.

VIII. National Publications:

1. Synthesis and Biological Evaluation of Imidazopyrimidine-Propenone Conjugates as Potent Tubulin Polymerization Inhibitors. MVPS Vishnuvardhan, I. Bin Sayeed, V. L. Nayak, **Mohd Adil Shareef** and Ahmed Kamal. *J. Chem and Pharm.Res.* 2017, *9*, 210-219.
2. Molecular docking and preclinical studies of *Gymnema sylvestre* on endothelial nitric oxide synthase in Type-2 diabetes-related complications. **Jour. Y. Pharm.** 2014, *6*, 26-32.

IX. National Conferences:

Papers Presented - None

X. International Conferences:

Papers Presented - None

XI. Chairperson/Judges/Organizing committee (If any):

Synchropharma-2014 (**Organizing committee**)

Synchropharma-2016 (**Organizing committee**)

XII. Workshops/FDP (Total number attended &List): 2

1. Ugc Sponsored Refresher Course “Acaademy industry interface transforming research thoughts into practice” 2014
2. “Good clinical practices and Good laboratory practices” conducted by GVK biosciences Hyderabad, 2014.

XIII. M.Pharm Projects (Total no. of projects): NIL

XIV. Ph.D. Projects:

Total number of Projects guiding: NIL

XV. Awards:

Awarded Junior Research Fellowship to carry out research by UGC-MANF, New Delhi, India (2015-2017)

Awarded Senior Research Fellowship to carry out research by UGC-MANF, New Delhi, India (2017-2019)